11/11
08:10 am
mura
Mural Oncology plc (NASDAQ: MURA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.
Low
Report
Mural Oncology plc (NASDAQ: MURA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.
10/17
08:55 am
mura
Mural Oncology plc (NASDAQ: MURA) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $18.00 price target on the stock.
Medium
Report
Mural Oncology plc (NASDAQ: MURA) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $18.00 price target on the stock.
10/4
08:30 am
mura
Mural Oncology 'undervalued,' initiated with Strong Buy at Raymond James
Low
Report
Mural Oncology 'undervalued,' initiated with Strong Buy at Raymond James
10/4
08:30 am
mura
Mural Oncology 'undervalued,' initiated with Strong Buy at Raymond James
Low
Report
Mural Oncology 'undervalued,' initiated with Strong Buy at Raymond James
10/4
08:06 am
mura
Mural Oncology plc (NASDAQ: MURA) is now covered by analysts at Raymond James. They set a "strong-buy" rating and a $18.00 price target on the stock.
Medium
Report
Mural Oncology plc (NASDAQ: MURA) is now covered by analysts at Raymond James. They set a "strong-buy" rating and a $18.00 price target on the stock.
10/4
08:06 am
mura
Mural Oncology plc (NASDAQ: MURA) is now covered by analysts at Raymond James. They set a "strong-buy" rating and a $18.00 price target on the stock.
Medium
Report
Mural Oncology plc (NASDAQ: MURA) is now covered by analysts at Raymond James. They set a "strong-buy" rating and a $18.00 price target on the stock.
10/4
07:51 am
mura
Rating for MURA
Medium
Report
Rating for MURA
10/4
07:51 am
mura
Rating for MURA
Medium
Report
Rating for MURA
10/4
06:27 am
mura
Mural Oncology initiated with bullish view at Raymond James
Medium
Report
Mural Oncology initiated with bullish view at Raymond James
10/4
06:27 am
mura
Mural Oncology initiated with bullish view at Raymond James
Medium
Report
Mural Oncology initiated with bullish view at Raymond James